Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Public ClinicalTrials.gov record NCT03865082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.
Study identification
- NCT ID
- NCT03865082
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2019
- Primary completion
- Feb 28, 2022
- Completion
- Mar 31, 2022
- Last update posted
- Feb 16, 2022
2019 – 2022
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner University Medical Center Tucson Campus | Tucson | Arizona | 85719 | — |
| University of Southern California/ Hoag Hospital Presbyterian | Newport Beach | California | 92663 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Solid Tumor trials
Other public records listing Solid Tumor. Sorted by last update posted; newest first. Not a recommendation.
- NCT03739827: Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors Recruiting
- NCT07793994: Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors Not yet recruiting
- NCT07703878: A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors Recruiting
- NCT06234098: Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors Recruiting
- NCT05390827: Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol Recruiting
- NCT05250284: The Intersection of Oncology Care and Worker Well-Being Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03865082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2022 · Synced Jul 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03865082 live on ClinicalTrials.gov.